注入型薬物送達の世界市場：薬物送達デバイス、薬物送達製剤...市場調査レポートについてご紹介

Table of Contents

1 Introduction (Page No. – 23)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders

2 Research Methodology (Page No. – 29)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Key Data From Primary Sources
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 36)

4 Premium Insights (Page No. – 39)
4.1 Injectable Drug Delivery Market, By Formulation
4.2 Injectable Drug Delivery Market, By Usage Pattern
4.3 Injectable Drug Delivery Market, By Mode of Administration
4.4 Injectable Drug Delivery Market, By Therapeutic Application
4.5 Geographical Snapshot

5 Market Overview (Page No. – 43)
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Type
5.2.2 By Therapeutic Application
5.2.3 By Usage Pattern
5.2.4 By Mode of Administration
5.2.5 By End User
5.2.6 By Region
5.3 Market Dynamics
5.4 Drivers
5.4.1 Rising Prevalence of Chronic Diseases
5.4.2 Increase in Demand for Self-Injection Devices
5.4.3 Growth of the Biologics Market
5.4.4 Technological Advancements
5.5 Restraints
5.5.1 Needlestick Injuries and Infections
5.6 Opportunities
5.6.1 Increase in Demand for Biosimilars and Generic Injectables
5.6.1.1 Biosimilars
5.6.1.2 Generic Injectables
5.6.2 Contraceptive Injectables
5.7 Challenges
5.7.1 Product Recalls
5.7.2 Regulatory Hurdles
5.7.3 Stability of Products
5.7.4 Sterility of Injections
5.7.5 Preference for Other Modes of Drug Delivery

6 Injectable Drug Delivery Market, By Type (Page No. – 60)
6.1 Introduction
6.2 Devices
6.2.1 Conventional Injection Devices
6.2.1.1 By Material
6.2.1.1.1 Glass
6.2.1.1.2 Plastic
6.2.1.2 By Product
6.2.1.2.1 Fillable Syringes
6.2.1.2.2 Prefilled Syringes
6.2.1.3 By Usability
6.2.1.3.1 Reusable Syringes
6.2.1.3.2 Disposable Syringes
6.2.2 Self-Injection Devices
6.2.2.1 Needle-Free Injectors
6.2.2.1.1 By Product
6.2.2.1.1.1 Fillable Needle-Free Injectors
6.2.2.1.1.2 Prefilled Needle-Free Injectors
6.2.2.1.2 By Technology
6.2.2.1.2.1 Jet-Based Needle-Free Injectors
6.2.2.1.2.2 Spring-Based Needle-Free Injectors
6.2.2.1.2.3 Laser-Powered Needle-Free Injectors
6.2.2.1.2.4 Vibration-Based Needle-Free Injectors
6.2.2.1.3 By Usability
6.2.2.1.3.1 Reusable Needle-Free Injectors
6.2.2.1.3.2 Disposable Needle-Free Injectors
6.2.2.2 Autoinjectors
6.2.2.2.1 By Product
6.2.2.2.1.1 Fillable Autoinjectors
6.2.2.2.1.2 Prefilled Autoinjectors
6.2.2.2.2 By Technology
6.2.2.2.2.1 Automated Autoinjectors
6.2.2.2.2.2 Manual Autoinjectors
6.2.2.2.3 By Design
6.2.2.2.3.1 Standardized Autoinjectors
6.2.2.2.3.2 Customized Autoinjectors
6.2.2.2.4 By Usability
6.2.2.2.4.1 Reusable Autoinjectors
6.2.2.2.4.2 Disposable Autoinjectors
6.2.2.3 Pen Injectors
6.2.2.3.1 By Product
6.2.2.3.1.1 Single-Chambered Pen Injectors
6.2.2.3.1.2 Dual-Chambered Pen Injectors
6.2.2.3.2 By Design
6.2.2.3.2.1 Standard Pen Injectors
6.2.2.3.2.2 Customized Pen Injectors
6.2.2.3.3 By Usability
6.2.2.3.3.1 Reusable Pen Injectors
6.2.2.3.3.2 Disposable Pen Injectors
6.2.2.4 Wearable Injectors
6.2.2.5 Other Devices
6.3 Formulations
6.3.1 Conventional Drug Delivery
6.3.1.1 Solutions
6.3.1.2 Reconstituted/Lyophilized Formulations
6.3.1.3 Suspensions
6.3.1.4 Emulsions
6.3.2 Novel Drug Delivery Formulations
6.3.2.1 Colloidal Dispersions
6.3.2.1.1 Liposomes
6.3.2.1.2 Niosomes
6.3.2.1.3 Polymeric/Mixed Micelles
6.3.2.1.4 Nanoparticles
6.3.2.1.4.1 Nanosuspensions
6.3.2.1.4.2 Nanoemulsions/Microemulsions
6.3.2.1.4.3 Solid-Lipid Nanoparticles
6.3.2.2 Microparticles
6.3.2.2.1 Microspheres
6.3.2.2.2 Microcapsules
6.3.3 Long-Acting Injection Formulations

7 Injectable Drug Delivery Market, By Therapeutic Application (Page No. – 110)
7.1 Introduction
7.2 Autoimmune Diseases
7.2.1 Rheumatoid Arthritis
7.2.2 Multiple Sclerosis
7.2.3 Crohn’s Disease
7.2.4 Psoriasis
7.2.5 Other Autoimmune Diseases
7.3 Hormonal Disorders
7.3.1 Diabetes
7.3.2 Anemia
7.3.3 Reproductive Health Disease
7.3.4 Antithrombotic/Thrombolytic Therapy
7.3.5 Osteoporosis
7.3.6 Growth Hormone Deficiency (GHD)
7.4 Orphan Diseases
7.5 Oncology
7.6 Others
7.6.1 Pain Management
7.6.2 Allergy Treatment
7.6.3 Aesthetic Treatments
7.6.4 Hepatitis C
7.6.5 Hemophilia

8 Injectable Drug Delivery Market, By Usage Pattern (Page No. – 133)
8.1 Introduction
8.2 Curative Care
8.3 Immunization
8.4 Other Usage Patterns (Blood Transfusion and Blood Products, and Contraceptives)

9 Injectable Drug Delivery Market, By Mode of Administration (Page No. – 138)
9.1 Introduction
9.2 Skin
9.3 Circulatory/Musculoskeletal
9.4 Organs
9.5 Central Nervous System

10 Injectable Drug Delivery Market, By End User (Page No. – 143)
10.1 Introduction
10.2 Hospitals and Clinics
10.3 Home Care Settings
10.4 Research Laboratories
10.5 Pharmaceutical and Biotechnology Companies
10.6 Other End Users

11 Injectable Drug Delivery Market, By Region (Page No. – 150)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (RoE)
11.4 Asia
11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. – 202)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situations & Trends
12.3.1 New Product Launches
12.3.2 FDA Approvals
12.3.3 Expansions and Investments
12.3.4 Acquisitions
12.3.5 Collaborations

13 Company Profiles (Page No. – 210)
13.1 Introduction
13.2 Baxter International, Inc.
13.2.1 Business Overview
13.2.2 Product Offerings
13.2.3 Recent Developments
13.2.4 MnM View
13.3 Becton, Dickinson and Company
13.3.1 Business Overview
13.3.2 Product Offerings
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Gerresheimer AG
13.4.1 Business Overview
13.4.2 Products Offered
13.4.3 Recent Developments
13.4.4 MnM View
13.5 Pfizer, Inc.
13.5.1 Business Overview
13.5.2 Products Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Schott AG
13.6.1 Business Overview
13.6.2 Product Offerings
13.6.3 Recent Developments
13.6.4 MnM View
13.7 Alkermes PLC
13.7.1 Business Overview
13.7.2 Products Offered
13.7.3 Recent Developments
13.8 ELI Lilly and Company
13.8.1 Business Overview
13.8.2 Products Offered
13.8.3 Recent Developments
13.9 Sandoz
13.9.1 Business Overview
13.9.2 Products Offered
13.9.3 Recent Developments
13.10 Terumo Corporation
13.10.1 Business Overview
13.10.2 Products Offered
13.10.3 Recent Developments
13.11 Teva Pharmaceutical Industries Ltd.
13.11.1 Business Overview
13.11.2 Product Offerings
13.11.3 Recent Developments

14 Appendix (Page No. – 235)
14.1 Insights From Industry Experts
14.2 Discussion Guide
14.3 Other Recent Developments
14.4 Available Customizations
14.5 RT: Real-Time Market Intelligence
14.6 Related Reports